Skip to content

PHARMAPLUS ROCOURT

Active
Private limited companyfounded 1979active for 47 yearsChaussée de Tongres 431, 4000 Liège, BelgiumKBO/BCE: BE 0419.680.693
Summary

The computed 12-month bankruptcy probability of PHARMAPLUS ROCOURT is 2.8% (moderate). The 2025 annual accounts show negative equity (-€28,859) and a net result of €32,216. Equity is growing by about 33% per year across the filed financial years. Its solvency ranks better than 10% of 4,937 sector peers (NACE 47, financial year 2025). The company has been active since 1979 and the Belgian Official Gazette contains no insolvency or warning signals.

Overview

Activity
Retail sale of pharmaceutical products
NACE 47730
1 site
Size
€400,037total assets 2025
Staff
3.3 FTE
Equity
-€28,859
Profit
€32,216
Financial health
51 Fair Checked score 2025
Bankruptcy probabilitywithin 12 months
2.8%
Structure
Parent
PHARMA INVEST MANAGEMENT · 98%
Accounts 108 days early2 of 4 deeds read
Why 51raises riskNegative equity -€28,8591 change of registered office in 24 monthsSector: Retail trade (NACE 47)Liquidity: current ratio 1.04, cash €24,128Show the evidence

Checked score

Score 2025
51 / 100
Fair
Probability in this band: 1.5% to 4.2%
Financially better than 47% of its sector peers (NACE 47, micro)
Financial strength · tick = 2024
Weak
Solvency 18+6
equity -7.2% of total assets
Liquidity 18-5
short-term debt 73.3% · cash 6.0%
Profitability 79+9
return on assets 8.1%
Bankruptcy probability, 12 months
2.8% Moderate
0%0.5%1.5%4%10%≥ 25%

About 3 in 100 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.6% (40,196 companies, NACE 47, micro)
Last 24 months 11-2024: 1.3% 12-2024: 1.3%● unchanged vs 11-2024 01-2025: 1.3%● unchanged vs 12-2024 02-2025: 1.3%● unchanged vs 01-2025 03-2025: 1.2%▼ -0.1 percentage points vs 02-2025 04-2025: 1.2%● unchanged vs 03-2025 05-2025: 1.2%● unchanged vs 04-2025 06-2025: 1.2%● unchanged vs 05-2025lowest value 07-2025: 1.3%▲ +0.1 percentage points vs 06-2025 08-2025: 1.4%▲ +0.1 percentage points vs 07-2025 09-2025: 1.4%● unchanged vs 08-2025 10-2025: 1.4%● unchanged vs 09-2025 11-2025: 1.4%● unchanged vs 10-2025 12-2025: 1.4%● unchanged vs 11-2025 01-2026: 1.4%● unchanged vs 12-2025 02-2026: 1.4%● unchanged vs 01-2026 03-2026: 1.4%● unchanged vs 02-2026 04-2026: 1.4%● unchanged vs 03-2026 05-2026: 1.8%▲ +0.4 percentage points vs 04-2026 06-2026: 1.8%● unchanged vs 05-2026 07-2026: 1.8%● unchanged vs 06-2026 08-2026: 1.8%● unchanged vs 07-2026 09-2026: 1.8%● unchanged vs 08-2026 10-2026: 2.8%▲ +1.0 percentage point vs 09-2026highest value
No credit on open account
Liquidity tight (current ratio 1.04, compared with 1.0 in 2024, below the usual 1.5; short-term debt: 73.3% and cash: 6% of total assets), and equity is negative.
How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, micro): better than 17% on solvency, 17% on liquidity, 69% on profitability and 87% on growth.

The bankruptcy probability was computed on 14-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Six signals.
raises riskneutral
raises risk · Negative equity -€28,859
NBB · annual accounts
raises risk · 1 change of registered office in 24 months
Belgian Official Gazette
raises risk · Sector: Retail trade (NACE 47)
KBO
raises risk · Liquidity: current ratio 1.04, cash €24,128
NBB · annual accounts
raises risk · Weak solvency vs sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 10% of 4937 sector peers (2025).
NBB · sector comparison
Position among 4937 sector peers
Solvency
better than 10%
← weakest strongest →
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 14-04-2026, 108 days ahead of the deadline.
NBB · 10 filings
Deviation from the deadline
2025
108 days early
2024
23 days early
2023
22 days early
2022
56 days early
2021
52 days early
2020
37 days early
2019
39 days early
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 48 days before the deadline; the sector median (NACE 47) for financial year 2024 is on the deadline day, and 47% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 9 June (4 of the last 5 filed years within 31 days of that day).
Companies Code · seven months
Where today falls in the filing period
15-10-2026 today31-12-2026 year end31-07-2027 deadline
neutral · No strike-offs in the KBO publications
Searched since 2021.
KBO publications · our coverage
  1. Resignation: VSF MANAGEMENT (director)Appointment: GFB MANAGEMENT (director) ·…
  2. Resignation: PHARMA INVEST MANAGEMENT SRL (director)Permanent representatives: PIRENNE Hubert and…
  3. Annual accounts filedfinancial year 2025 · full…

Key points

  • Risk: Negative equityfinancial year 2025: debts exceed assets -€28,859 View
  • Caution: Among the weakest 10% on solvencysector median 36.2% · 4,937 companies -7.2% View
  • Board changedlatest change 02-09-2026 · 2 in office 2 joined · 1 left View
  • Positive: Filed on time since financial year 2018accounts within the deadline every year 8 years View
  • Controlled by PHARMA INVEST MANAGEMENT 98% View
  • Positive: 5 profitable years in a rowprofit 2025: €32,216 5 years View
  • Active since 1979founded 30-03-1979 47 years View

By topic

Financials

Financial year
2025
Total assets
€400,037
Profit
€32,216
Solvency
-7.2%
Total assets▼ 14.0%
Net result
20182025
Go to Financials

Board & ownership

Board
2 members
Parent
PHARMA INVEST MANAGEMENT · 98%
  • GFB MANAGEMENTDirector
  • VSF MANAGEMENT SRLDirector
Go to Board & ownership

Timeline

Events
51
Since
1980
Next accounts
by 31-07-2027
  1. 08-07-2025Annual accounts filed
  2. 09-07-2024Annual accounts filed
  3. 05-06-2023Annual accounts filed
Go to Timeline

Company details

Sites
1
Legal form
Private limited company
Activity
Retail sale of pharmaceutical productsNACE 47730
Founded
30-03-1979
Year ends
31-12
Peppol
Reachable for e-invoices
Go to Company details

Go further with this company

Your own company? See how customers, suppliers and banks see it and what to improve first.

Investigating this company? Keep it with today's facts in a case file.